Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06613009
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-22
Brief Title:
Study of IBI3009 in Subjects With Unresectable Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase I Multicenter Open-label Study of IBI3009 in Subjects With Unresectable Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to evaluate the safety and tolerability of IBI3009 and to determine the maximum tolerated dose MTD andor the recommended Phase 2 Dose RP2D of IBI3009
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None